香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：379） 終止根據舊協議出售物業之 須予披露交易 及 根據新協議出售物業之 主要交易 終止舊協議 誠如本公司日期為二零二五年五月二十三日之公告所披露，賣方（本公司之間接全資附屬公司） 已與吉諾賽爾訂立舊協議，以出售103物業。 董事會宣佈，經訂約方公平磋商後，於二零二五年九月九日（聯交所交易時段後），賣方與吉諾 賽爾訂立終止協議，據此，雙方同意(i)自終止協議日期起終止舊協議；及(ii)於自索萊寶（即新協 議及五份協議項下之買方）收到新代價後7日內，賣方退還吉諾賽爾根據舊協議初步向賣方支付 之初始按金人民幣1,259,168.40元（相等於約1,372,000港元）。 訂立新協議 董事會進一步宣佈，於二零二五年九月九日（聯交所交易時段後），賣方同意出售，而索萊寶同 意購買103物業，新代價為人民幣6,368,208元（相等於約6,941,000港元）。索萊寶 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國恒嘉融資租賃集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 第 2 頁 共 10 頁 v 1.1.1 FF301 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00379 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 4,00 ...

Company Overview - China Hengjia Leasing Group Co., Ltd. is a limited liability exempt company registered in the Cayman Islands, listed on the Hong Kong Stock Exchange since 2002 under stock code 00379. The company operates in the trade of medical, health, and personal hygiene products, manufacturing and selling health foods and nutritional supplements, as well as property and financial investments [2]. Financial Performance - As of June 30, 2025, the company reported total operating revenue of HKD 36.36 million, a year-on-year decrease of 15.2%. The net profit attributable to shareholders was -HKD 34.34 million, an increase of 13.62% year-on-year. The gross profit margin stood at 18.3%, and the debt-to-asset ratio was 13.07% [1][3]. Stock Performance - On August 25, the Hang Seng Index rose by 1.94%, closing at 25,829.91 points. Hengjia Leasing's stock closed at HKD 0.09 per share, up 21.62%, with a trading volume of 800,000 shares and a turnover of HKD 72,600. The stock experienced a volatility of 31.08%. Over the past month, the stock has seen a cumulative decline of 2.63%, while year-to-date, it has increased by 124.24%, outperforming the Hang Seng Index by 26.32% [1]. Valuation Metrics - Currently, there are no institutional investment ratings for Hengjia Leasing. The average price-to-earnings (P/E) ratio for the other financial industry is 16.65 times, with a median of -0.19 times. Hengjia Leasing's P/E ratio is -1.67 times, ranking 151st in the industry. Comparatively, other companies in the sector have P/E ratios of 2.62 times (China Merchants China Fund), 3.03 times (Weixin Jinkou), 4.04 times (Hong Kong Credit), 4.42 times (Guoyin Financial Leasing), and 4.56 times (Qifu Technology) [1].

Core Viewpoint - Hengjia Financing Leasing (00379) announced the sale of a property located in Shanghai for a total consideration of RMB 35.404 million [1] Summary by Relevant Sections - **Transaction Details** - The seller, a wholly-owned subsidiary of the company, Shanghai Lizu Biotechnology Co., Ltd., plans to sell the property to Shanghai Solabio Biochemical Technology Co., Ltd. [1] - The total consideration for the property is RMB 35.404 million [1] - **Property Specifications** - The property is located at No. 188, Xin Jun Huan Road, Minhang District, Shanghai, and consists of units 102, 302, 303, 402, and 403 [1] - The total building area of the property is approximately 4,165.21 square meters [1] - The property is designated for industrial use [1]

Core Viewpoint - Hengjia Financing Leasing (00379) announced the sale of a property by its indirect wholly-owned subsidiary, Shanghai Lizu Biotechnology Co., Ltd., to Shanghai Solabio Biochemical Technology Co., Ltd. for a total consideration of RMB 35.404 million [1] Summary by Relevant Sections - **Transaction Details** - The property is located at No. 188, Xin Jun Huan Road, Minhang District, Shanghai, China [1] - The total construction area of the property is approximately 4,165.21 square meters [1] - The property is designated for industrial use [1]

Core Viewpoint - Hengjia Financing Leasing (00379.HK) announced a conditional agreement for the sale of a property located in Shanghai for a total consideration of RMB 35.4043 million [1] Group 1: Transaction Details - The seller is Shanghai Lizu Biotechnology Co., Ltd., an indirect wholly-owned subsidiary of the company [1] - The buyer is Shanghai Solabio Biotech Co., Ltd. [1] - The property is located at No. 188, Xin Jun Huan Road, Minhang District, Shanghai, with a total construction area of approximately 4,165.21 square meters [1] Group 2: Property Usage - The property is designated for industrial use [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：379） 有關出售物業之主要交易 出售事項 於二零二五年八月二十二日（交易時段後），賣方（本公司之間接全資附屬公司）與買方訂立協 議，據此，賣方有條件同意出售而買方有條件同意購買物業，總代價為人民幣35,404,285元（相等 於約38,591,000港元）。 上市規則之涵義 由於根據上市規則就出售事項及其項下擬進行之交易計算之一項或多項適用百分比率高於25% 但均低於75%，出售事項根據上市規則第14章構成本公司之一項主要交易，並須遵守上市規則 第14章項下之申報、公告、通函及股東批准規定。 股東特別大會 本公司將召開及舉行股東特別大會，以供股東審議及酌情批准出售事項、協議及其項下擬進行 之交易。股東特別大會上就出售事項之表決將以投票方式進行。據董事經作出一切合理查詢後 所深知、盡悉及確信，概無股東或其任何聯繫人於出售事項、協議及其項下擬進行之交易中擁 有 ...

Group 1 - The core viewpoint of the article highlights that Hengjia Financing Leasing (00379) reported a total revenue of HKD 39.874 million for the six months ending June 30, 2025, representing a year-on-year decline of 15.2% [1] - The company experienced a net loss of HKD 37.653 million, which is a reduction of 13.6% compared to the previous year [1] - The basic loss per share was reported at HKD 0.0223 [1] Group 2 - The decline in revenue is primarily attributed to decreased sales in daily necessities, healthcare, and hygiene products in Hong Kong [1] - The reduction in net loss is mainly due to tighter control over administrative expenses [1]

Core Insights - 恒嘉融资租赁(00379) reported a total revenue of HKD 39.874 million for the six months ending June 30, 2025, representing a year-on-year decline of 15.2% [1] - The company recorded a net loss of HKD 37.653 million, which is a reduction of 13.6% compared to the previous year [1] - Basic loss per share was HKD 0.0223 [1] Revenue Analysis - The decline in revenue was primarily attributed to decreased sales in daily consumer goods, healthcare, and hygiene products in Hong Kong [1] Loss Reduction Factors - The reduction in net loss was mainly due to tighter control over administrative expenses [1]

[Interim Results Summary](index=1&type=section&id=Interim%20Results%20Summary) [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=1&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the six months ended June 30, 2025, the Group's unaudited interim results show total revenue decreased by 15.2% to HK$39,874 thousand, gross profit decreased by 34.4% to HK$7,296 thousand, and loss for the period narrowed by 13.6% to HK$37,653 thousand, with basic and diluted loss per share of 2.23 HK cents Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (For the six months ended June 30) | Metric | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Total Revenue | 39,874 | 47,023 | -15.2% | | Cost of Revenue | (32,578) | (35,893) | -9.2% | | Gross Profit | 7,296 | 11,130 | -34.4% | | Other Income | 90 | 113 | -20.4% | | Other Gains and Losses | (13,266) | (14,276) | -7.1% | | Administrative Expenses | (16,190) | (21,863) | -26.0% | | Impairment Losses | (559) | (2,655) | -79.0% | | Share of Results of Associates | (14,764) | (15,877) | -7.0% | | Finance Costs | (260) | (144) | +80.6% | | Loss Before Tax | (37,653) | (43,572) | -13.6% | | Income Tax Expense | – | (19) | -100.0% | | Loss for the Period | (37,653) | (43,591) | -13.6% | | Total Comprehensive Expense for the Period | (28,479) | (54,536) | -47.8% | | Basic and Diluted Loss Per Share | (2.23) HK Cents | (2.58) HK Cents | -13.6% | [Condensed Consolidated Statement of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the Group's total assets were HK$359,365 thousand, an 8.4% decrease from December 31, 2024. Total liabilities were HK$46,963 thousand, an 8.9% decrease, and net assets declined to HK$312,402 thousand Condensed Consolidated Statement of Financial Position (As of June 30) | Metric | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Non-current Assets | 295,946 | 324,253 | -8.7% | | Current Assets | 63,419 | 68,203 | -7.0% | | **Total Assets** | **359,365** | **392,456** | **-8.4%** | | Current Liabilities | 44,588 | 48,156 | -7.4% | | Non-current Liabilities | 2,375 | 3,419 | -30.6% | | **Total Liabilities** | **46,963** | **51,575** | **-8.9%** | | Share Capital | 168,730 | 168,730 | 0.0% | | Reserves | 143,672 | 172,151 | -16.5% | | **Total Equity** | **312,402** | **340,881** | **-8.3%** | [Notes to the Condensed Consolidated Financial Statements](index=5&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) [Company Information](index=5&type=section&id=1.%20Company%20Information) The Company is a listed entity incorporated in the Cayman Islands with shares listed on the Hong Kong Stock Exchange, primarily engaged in sales of daily necessities, healthcare and hygiene products, food products and nutritional supplements, equity securities trading, property investment, investment holding, and money lending in Hong Kong and China - The company is a listed entity incorporated in the Cayman Islands, with shares listed on the Hong Kong Stock Exchange[8](index=8&type=chunk) - Principal businesses include sales of daily necessities, healthcare and hygiene products, production and sales of food products and nutritional supplements, equity securities trading, property investment, investment holding, and money lending businesses[8](index=8&type=chunk) [Basis of Preparation and Accounting Policies](index=5&type=section&id=2.%20Basis%20of%20Preparation%20and%20Accounting%20Policies) The interim condensed consolidated financial statements are prepared in accordance with HKAS 34 and the Listing Rules, with accounting policies consistent with the 2024 annual consolidated financial statements, except for new standards effective January 1, 2025. Management exercised significant judgment and estimates in their preparation - The financial statements are prepared in accordance with HKAS 34 and the Listing Rules, with accounting policies largely consistent with the 2024 annual statements[9](index=9&type=chunk) - The Group has not early adopted new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective[9](index=9&type=chunk)[11](index=11&type=chunk) - Preparation of the statements involves significant management judgments and estimates, and actual results may differ[9](index=9&type=chunk)[12](index=12&type=chunk) [Revenue Analysis](index=6&type=section&id=5.%20Revenue%20Analysis) Total revenue for the first half of 2025 was HK$39,874 thousand, a 15.2% year-on-year decrease, with customer contract revenue (mainly from sales of daily necessities, healthcare, and hygiene products) at HK$37,212 thousand and rental income at HK$2,662 thousand, primarily from the Hong Kong market Revenue Sources (For the six months ended June 30) | Revenue Source | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Sales of daily necessities, healthcare and hygiene products | 35,803 | 42,002 | -14.8% | | Sales of food products and nutritional supplements | 1,409 | 1,855 | -24.0% | | Rental income | 2,662 | 3,166 | -15.9% | | **Total Revenue** | **39,874** | **47,023** | **-15.2%** | - Revenue is primarily recognized when customers obtain control of goods, typically upon delivery and acceptance[14](index=14&type=chunk) - Geographical revenue primarily originated from Hong Kong (**HK$35,803 thousand**), with China contributing **HK$1,409 thousand**[14](index=14&type=chunk) [Segment Information](index=7&type=section&id=6.%20Segment%20Information) The Group is organized into three reportable segments based on operational nature: distribution, manufacturing, and investment. The finance lease segment has no related items this period as the associate is no longer classified as such. Segment results exclude certain other income, gains and losses, share of results of associates, and corporate expenses - The Group's principal operating segments include distribution (daily necessities, healthcare, and hygiene products in Hong Kong), manufacturing (food products and nutritional supplements in China), and investment (investment properties in China, Hong Kong securities, and money lending)[17](index=17&type=chunk) - The finance lease segment had no related items during the current period, as Beijing Hengjia Group is no longer classified as an associate[16](index=16&type=chunk) [Segment Revenue and Results](index=8&type=section&id=Segment%20Revenue%20and%20Results) In the first half of 2025, the distribution segment reported HK$35,803 thousand in revenue and a loss of HK$1,792 thousand; the manufacturing segment had HK$1,409 thousand in revenue and a loss of HK$2,425 thousand; the investment segment generated HK$2,662 thousand in revenue and a loss of HK$11,632 thousand, with no revenue or results from the finance lease segment Segment Revenue and Results (For the six months ended June 30) | Segment | 2025 Revenue (HK$ Thousand) | 2024 Revenue (HK$ Thousand) | Revenue Change (%) | 2025 Results (HK$ Thousand) | 2024 Results (HK$ Thousand) | Results Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Distribution | 35,803 | 42,002 | -14.8% | (1,792) | (887) | +102.0% | | Manufacturing | 1,409 | 1,855 | -24.0% | (2,425) | (2,454) | -1.2% | | Investment | 2,662 | 3,166 | -15.9% | (11,632) | (14,348) | -19.0% | | Finance Lease | – | – | N/A | – | (15,553) | -100.0% | | **Total** | **39,874** | **47,023** | **-15.2%** | **(15,849)** | **(33,242)** | **-52.3%** | - All segment revenue was derived from external customers[19](index=19&type=chunk) [Segment Assets and Liabilities](index=9&type=section&id=Segment%20Assets%20and%20Liabilities) As of June 30, 2025, the distribution segment had assets of HK$42,250 thousand and liabilities of HK$4,556 thousand; the manufacturing segment had assets of HK$45,546 thousand and liabilities of HK$5,938 thousand; the investment segment had assets of HK$177,803 thousand and liabilities of HK$6,931 thousand, with interests in associates totaling HK$75,094 thousand Segment Assets and Liabilities (As of June 30) | Segment | 2025 Assets (HK$ Thousand) | 2024 Assets (HK$ Thousand) | Assets Change (%) | 2025 Liabilities (HK$ Thousand) | 2024 Liabilities (HK$ Thousand) | Liabilities Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Distribution | 42,250 | 46,567 | -9.2% | 4,556 | 7,315 | -37.7% | | Manufacturing | 45,546 | 46,376 | -1.8% | 5,938 | 5,946 | -0.1% | | Investment | 177,803 | 188,012 | -5.4% | 6,931 | 7,349 | -5.7% | | Interests in Associates | 75,094 | 91,442 | -17.9% | – | – | N/A | | **Total** | **359,365** | **392,456** | **-8.4%** | **46,963** | **51,575** | **-8.9%** | - Most assets and liabilities are allocated to reportable and operating segments, with the exception of a few corporate items[22](index=22&type=chunk) [Details of Other Financial Items](index=9&type=section&id=Details%20of%20Other%20Financial%20Items) This section details the composition and changes in other income, other gains and losses, impairment losses, finance costs, and loss for the period [Other Income](index=9&type=section&id=7.%20Other%20Income) Other income for the first half of 2025 was HK$90 thousand, a 20.4% year-on-year decrease, primarily from interest income from banks and non-bank financial institutions and government grants Other Income (For the six months ended June 30) | Income Source | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Interest income from banks and non-bank financial institutions | 33 | 65 | -49.3% | | Government grants | 54 | – | N/A | | Miscellaneous income | 3 | 48 | -93.8% | | **Total** | **90** | **113** | **-20.4%** | [Other Gains and Losses](index=10&type=section&id=8.%20Other%20Gains%20and%20Losses) Net other gains and losses for the first half of 2025 amounted to a loss of HK$13,266 thousand, a 7.1% year-on-year decrease, primarily comprising fair value losses on investment properties of HK$10,876 thousand and fair value losses on financial assets at fair value through profit or loss of HK$1,823 thousand Other Gains and Losses (For the six months ended June 30) | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Fair value changes on financial assets at fair value through profit or loss | (1,823) | (871) | +109.3% | | Fair value changes on investment properties | (10,876) | (12,991) | -16.3% | | Net exchange losses | (7) | (28) | -75.0% | | Write-off of property, plant and equipment | – | (145) | -100.0% | | Write-off of trade receivables | (31) | – | N/A | | Write-off of inventories | (192) | (129) | +48.8% | | Loss on remeasurement of assets classified as held for sale | (337) | – | N/A | | Others | – | (112) | -100.0% | | **Total** | **(13,266)** | **(14,276)** | **-7.1%** | [Impairment Losses under Expected Credit Loss Model](index=10&type=section&id=9.%20Impairment%20Losses%20under%20Expected%20Credit%20Loss%20Model) Total impairment losses for the first half of 2025 amounted to HK$559 thousand, a significant 79.0% year-on-year decrease, primarily due to impairment of other receivables, with no impairment losses on loans receivable this period Impairment Losses under Expected Credit Loss Model (For the six months ended June 30) | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Loans receivable | – | 1,400 | -100.0% | | Other receivables | 559 | 1,255 | -55.5% | | **Total** | **559** | **2,655** | **-79.0%** | [Finance Costs](index=10&type=section&id=10.%20Finance%20Costs) Finance costs for the first half of 2025 were HK$260 thousand, an 80.6% year-on-year increase, primarily due to higher interest on lease liabilities and bank borrowings Finance Costs (For the six months ended June 30) | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Interest on bank borrowings | 51 | 23 | +121.7% | | Interest on lease liabilities | 155 | 63 | +146.0% | | Interest on other loans | 54 | 58 | -6.9% | | **Total** | **260** | **144** | **+80.6%** | [Income Tax Expense](index=11&type=section&id=11.%20Income%20Tax%20Expense) Income tax expense for the first half of 2025 was zero, compared to HK$19 thousand in the same period of 2024, primarily due to a reduction in China corporate income tax Income Tax Expense (For the six months ended June 30) | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Current tax – China corporate income tax | – | 22 | -100.0% | | Over-provision in prior years – Hong Kong profits tax | – | (3) | -100.0% | | **Income Tax Expense** | **–** | **19** | **-100.0%** | [Components of Loss for the Period](index=11&type=section&id=12.%20Components%20of%20Loss%20for%20the%20Period) The loss for the first half of 2025 was primarily composed of cost of inventories sold of HK$32,578 thousand, staff costs of HK$8,349 thousand, and total depreciation of HK$2,543 thousand Components of Loss for the Period (For the six months ended June 30) | Item | 2025 (HK$ Thousand) | 2024 (HK$ Thousand) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Depreciation of property, plant and equipment | 353 | 128 | +175.8% | | Depreciation of right-of-use assets | 2,190 | 1,794 | +22.1% | | **Total Depreciation** | **2,543** | **1,922** | **+32.3%** | | Cost of inventories sold | 32,578 | 35,893 | -9.2% | | Staff costs | 8,349 | 11,154 | -25.2% | | Short-term lease expenses | 194 | 591 | -67.2% | [Dividends and Loss Per Share](index=11&type=section&id=Dividends%20and%20Loss%20Per%20Share) The Board does not recommend an interim dividend for the first half of 2025, and basic and diluted loss per share for the period was 2.23 HK cents, a narrowing compared to the prior year [Dividends](index=11&type=section&id=13.%20Dividends) The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025 - The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025[30](index=30&type=chunk) [Loss Per Share Attributable to Owners of the Company](index=12&type=section&id=14.%20Loss%20Per%20Share%20Attributable%20to%20Owners%20of%20the%20Company) Loss attributable to owners of the Company for the period was HK$37,653 thousand, with basic and diluted loss per share of 2.23 HK cents, a narrowing compared to the same period last year Loss Per Share Attributable to Owners of the Company (For the six months ended June 30) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Loss for the period attributable to owners of the Company | (37,653) HK$ Thousand | (43,591) HK$ Thousand | | Weighted average number of ordinary shares | 1,687,303 Thousand Shares | 1,687,303 Thousand Shares | | **Basic and Diluted Loss Per Share** | **(2.23) HK Cents** | **(2.58) HK Cents** | - The Company had no dilutive potential ordinary shares during the current and prior periods, thus diluted loss per share is the same as basic loss per share[31](index=31&type=chunk) [Receivables and Payables](index=12&type=section&id=Receivables%20and%20Payables) This section details the composition and aging analysis of trade receivables, other receivables, deposits and prepayments, and trade and other payables, illustrating changes in each account [Trade Receivables](index=12&type=section&id=15.%20Trade%20Receivables) As of June 30, 2025, net trade receivables amounted to HK$7,736 thousand, a 16.9% decrease from December 31, 2024, with an increase in receivables aged 31-90 days and 91-270 days Trade Receivables (As of June 30) | Metric | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Trade receivables | 7,910 | 9,760 | -18.9% | | Less: Impairment allowance | (174) | (457) | -61.9% | | **Net Trade Receivables** | **7,736** | **9,303** | **-16.9%** | Aging Analysis of Trade Receivables (As of June 30) | Aging | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | 0-30 days | 1,956 | 4,786 | -59.1% | | 31-90 days | 3,097 | 2,499 | +23.9% | | 91-270 days | 1,961 | 1,334 | +47.0% | | Over 270 days | 722 | 684 | +5.6% | | **Total** | **7,736** | **9,303** | **-16.9%** | - The credit period granted to customers ranges from **0 to 60 days**[32](index=32&type=chunk) [Other Receivables, Deposits and Prepayments](index=13&type=section&id=16.%20Other%20Receivables%2C%20Deposits%20and%20Prepayments) As of June 30, 2025, total other receivables, deposits, and prepayments amounted to HK$14,362 thousand, a 13.2% decrease from December 31, 2024, with impairment allowance increasing to HK$5,749 thousand Other Receivables, Deposits and Prepayments (As of June 30) | Item | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Other receivables | 11,709 | 12,589 | -7.0% | | Prepayments | 1,179 | 1,552 | -24.1% | | Prepayments for purchases of goods | 6,582 | 6,949 | -5.3% | | Deposits | 641 | 642 | -0.2% | | **Subtotal** | **20,111** | **21,732** | **-7.5%** | | Less: Impairment allowance | (5,749) | (5,190) | +10.8% | | **Total** | **14,362** | **16,542** | **-13.2%** | [Trade and Other Payables](index=14&type=section&id=17.%20Trade%20and%20Other%20Payables) As of June 30, 2025, total trade and other payables amounted to HK$20,638 thousand, a 15.2% decrease from December 31, 2024, with a significant reduction in trade payables aged 0-30 days and 31-90 days Trade and Other Payables (As of June 30) | Item | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | Trade payables | 860 | 2,383 | -63.9% | | Accrued expenses | 6,300 | 8,050 | -21.7% | | Receipts in advance | 5,099 | 6,658 | -23.4% | | Deposits received | 1,380 | – | N/A | | Other payables | 6,999 | 7,263 | -3.6% | | **Total** | **20,638** | **24,354** | **-15.2%** | Aging Analysis of Trade Payables (As of June 30) | Aging | June 30, 2025 (HK$ Thousand) | December 31, 2024 (HK$ Thousand) | Change (%) | | :--- | :--- | :--- | :--- | | 0-30 days | 293 | 705 | -58.5% | | 31-90 days | 40 | 1,031 | -96.1% | | 91-270 days | 1 | 136 | -99.3% | | Over 270 days | 526 | 511 | +2.9% | | **Total** | **860** | **2,383** | **-63.9%** | - Deposits received include a deposit of RMB1,259,000 (approximately **HK$1,380,000**) for the disposal of an investment property classified as held for sale[34](index=34&type=chunk) [Management Discussion and Analysis](index=15&type=section&id=Management%20Discussion%20and%20Analysis) [Business Review](index=15&type=section&id=Business%20Review) The Group's total revenue decreased by 15.2% year-on-year, gross profit by 34.4%, and net loss narrowed by 13.6% in the first half of 2025, with all business segments (distribution, manufacturing, investment) facing challenges and declining revenue, though the investment segment's loss narrowed - The Group's total revenue was **HK$39.9 million**, a **15.2% year-on-year decrease**; gross profit was **HK$7.3 million**, a **34.4% year-on-year decrease**; and net loss was **HK$37.7 million**, a **13.6% year-on-year decrease**[36](index=36&type=chunk) - The Group operates three segments: distribution, manufacturing, and investment, in China and Hong Kong[37](index=37&type=chunk) [Distribution Segment](index=15&type=section&id=Distribution%20Segment) The distribution segment's revenue decreased by 14.8% year-on-year to HK$35.8 million, recording a net loss of HK$1.8 million, primarily due to changing consumption patterns and reduced supply of traditional Chinese medicine products Distribution Segment Performance (For the six months ended June 30) | Metric | 2025 (HK$ Million) | 2024 (HK$ Million) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 35.8 | 42.0 | -14.8% | | Net Loss | (1.8) | (0.9) | +100.0% | - The decrease in revenue was mainly due to underperformance of own-brand health and wellness products, and reduced supply of traditional Chinese medicine products due to packaging changes and the suspension of approval for continuing connected transactions[38](index=38&type=chunk) [Manufacturing Segment](index=15&type=section&id=Manufacturing%20Segment) The manufacturing segment's revenue decreased by 26.3% year-on-year to HK$1.4 million, with a net loss of HK$2.4 million, a slight narrowing of loss, facing challenges from intense competition in the Chinese food market and limited production scale hindering cost reduction Manufacturing Segment Performance (For the six months ended June 30) | Metric | 2025 (HK$ Million) | 2024 (HK$ Million) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 1.4 | 1.9 | -26.3% | | Net Loss | (2.4) | (2.5) | -4.0% | - Extremely low sales and a recorded loss were primarily impacted by intense competition in the Chinese food market and limited production scale making product cost reduction difficult[39](index=39&type=chunk) [Investment Segment](index=16&type=section&id=Investment%20Segment) The investment segment's revenue decreased by 15.9% year-on-year to HK$2.7 million, mainly due to an early lease termination by a tenant, while net loss narrowed to HK$11.6 million, primarily benefiting from reduced fair value losses on investment properties, and the Group has signed an agreement to dispose of a property in Shanghai Investment Segment Performance (For the six months ended June 30) | Metric | 2025 (HK$ Million) | 2024 (HK$ Million) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 2.7 | 3.2 | -15.9% | | Net Loss | (11.6) | (14.3) | -19.0% | - The decrease in revenue was primarily due to an early lease termination by a tenant[40](index=40&type=chunk) - The reduction in loss was mainly attributable to a decrease in fair value losses on investment properties in China from **HK$13.0 million** to **HK$10.9 million**[40](index=40&type=chunk) - The Group has agreed to dispose of a property in Minhang District, Shanghai, for RMB6,295,842 (approximately **HK$6,844,000**), with completion expected on or before August 30, 2025[40](index=40&type=chunk) [Financial Review](index=16&type=section&id=Financial%20Review) This section provides a detailed analysis of changes in the Group's financial metrics, noting that total revenue declined due to Hong Kong daily necessities sales, gross margin decreased due to discounts and rising costs, administrative expenses significantly reduced due to staff cost control, and associate losses primarily stemmed from Top Insight Limited [Revenue](index=16&type=section&id=Revenue) Revenue for the period was HK$39.9 million, a 15.2% year-on-year decrease, primarily due to lower sales of daily necessities, healthcare, and hygiene products in Hong Kong - Revenue was **HK$39.9 million**, a **15.2% year-on-year decrease**, primarily due to lower sales of daily necessities, healthcare, and hygiene products in Hong Kong[41](index=41&type=chunk) [Gross Profit](index=16&type=section&id=Gross%20Profit) Gross profit for the period was HK$7.3 million, a 34.4% year-on-year decrease, with gross margin falling from 23.7% to 18.3%, mainly due to higher trade discounts offered to bulk buyers and increased costs for certain products - Gross profit was **HK$7.3 million**, a **34.4% year-on-year decrease**[42](index=42&type=chunk) - Gross profit margin decreased from **23.7% to 18.3%**, attributed to higher trade discounts offered to bulk buyers and increased costs for certain products[42](index=42&type=chunk) [Other Income](index=16&type=section&id=Other%20Income) Other income for the period was HK$90 thousand, a 20.4% year-on-year decrease, primarily from bank fixed deposit interest income and a one-off Chinese government grant - Other income was **HK$90 thousand**, a **20.4% year-on-year decrease**, primarily from bank fixed deposit interest income and a one-off Chinese government grant[43](index=43&type=chunk) [Other Gains and Losses](index=17&type=section&id=Other%20Gains%20and%20Losses) Net other gains and losses for the period resulted in a HK$13.3 million loss, a 7.1% year-on-year decrease, primarily comprising fair value losses on investment properties of HK$10.9 million and fair value losses on financial assets at fair value through profit or loss of HK$1.8 million - Net other gains and losses resulted in a **HK$13.3 million loss**, a **7.1% year-on-year decrease**[44](index=44&type=chunk) - This primarily included fair value losses on investment properties of **HK$10.9 million** (a **16.2% year-on-year decrease**) and fair value losses on financial assets at fair value through profit or loss of **HK$1.8 million** (a **100% year-on-year increase**)[44](index=44&type=chunk) [Administrative Expenses](index=17&type=section&id=Administrative%20Expenses) Administrative expenses for the period were HK$16.2 million, a 25.9% year-on-year decrease, primarily comprising staff costs of HK$8.3 million, legal and professional fees, depreciation, and various administrative expenses - Administrative expenses were **HK$16.2 million**, a **25.9% year-on-year decrease**[45](index=45&type=chunk) - This primarily included staff costs of **HK$8.3 million** (a **25.6% year-on-year decrease**), legal and professional fees, depreciation, and various administrative expenses[45](index=45&type=chunk) [Share of Results of Associates](index=17&type=section&id=Share%20of%20Results%20of%20Associates) Share of results of associates for the period was a loss of HK$14.8 million, a 7.0% year-on-year decrease, primarily due to the share of loss from Top Insight Limited, with no related share of loss from Beijing Hengjia Group as it is no longer classified as an associate - Share of results of associates was a **HK$14.8 million loss**, a **7.0% year-on-year decrease**[46](index=46&type=chunk) - This primarily included a share of loss from Top Insight Limited of **HK$14.7 million** (compared to a profit of **HK$800 thousand** in the prior year) and a loss from Simagi Finance Company Limited of **HK$34 thousand**[46](index=46&type=chunk) - Beijing Hengjia Group, no longer classified as an associate, had no related share of loss this period (compared to a **HK$15.6 million loss** in the prior year)[46](index=46&type=chunk) [Loss for the Period Attributable to Owners of the Company](index=17&type=section&id=Loss%20for%20the%20Period%20Attributable%20to%20Owners%20of%20the%20Company) Net loss attributable to owners of the Company for the period was HK$37.7 million, a 13.6% year-on-year decrease, primarily due to tightened control over administrative expenses - Net loss for the period was **HK$37.7 million**, a **13.6% year-on-year decrease**[47](index=47&type=chunk) - The reduction in loss was primarily due to tightened control over administrative expenses[47](index=47&type=chunk) [Financial Position and Liquidity](index=17&type=section&id=Financial%20Position%20and%20Liquidity) The Group's total assets and liabilities both decreased, while the gearing ratio and current ratio remained stable, with cash and cash equivalents declining primarily due to net cash outflow from operating activities [Financial Position](index=17&type=section&id=Financial%20Position) As of June 30, 2025, the Group's total assets were HK$359.4 million, an 8.4% year-on-year decrease; total liabilities were HK$47.0 million, an 8.9% year-on-year decrease, with both the gearing ratio and current ratio remaining stable Financial Position Overview (As of June 30) | Metric | June 30, 2025 (HK$ Million) | December 31, 2024 (HK$ Million) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 359.4 | 392.5 | -8.4% | | Total Liabilities | 47.0 | 51.6 | -8.9% | | Gearing Ratio | 13.1% | 13.1% | 0.0% | | Current Ratio | 1.4 | 1.4 | 0.0% | - The decrease in total assets was primarily due to fair value losses on investment properties in China and unsatisfactory operating results of associates[48](index=48&type=chunk) - The decrease in total liabilities was mainly due to a reduction in trade and other payables[48](index=48&type=chunk) [Liquidity and Financial Resources](index=18&type=section&id=Liquidity%20and%20Financial%20Resources) As of June 30, 2025, the Group's cash and cash equivalents were approximately HK$8.7 million, a decrease of HK$4.5 million from the beginning of the period, primarily due to net cash outflow from operating activities, while short-term bank borrowings remained stable - Cash and cash equivalents were approximately **HK$8.7 million**, a **HK$4.5 million decrease** from December 31, 2024, primarily due to net cash outflow from operating activities[50](index=50&type=chunk) - Short-term bank borrowings amounted to **HK$2.8 million**, remaining stable compared to the beginning of the period[50](index=50&type=chunk) - The Group finances its business operations through funding from banks and other non-bank financial institutions, as well as internally generated cash flows[50](index=50&type=chunk) [Risk Management](index=18&type=section&id=Risk%20Management) The Group faces no significant foreign exchange risk and has not engaged in hedging, with credit risk primarily stemming from loans receivable, for which policies and procedures are in place to mitigate risk, assessed using an expected credit loss model [Foreign Exchange Risk](index=18&type=section&id=Foreign%20Exchange%20Risk) The Group is not exposed to significant foreign currency exchange rate fluctuation risk, as major transactions are denominated in local currencies, and no foreign exchange hedging transactions or instruments were entered into during the reporting period - The Group is not exposed to significant foreign currency exchange rate fluctuation risk, as major transactions are denominated in local currencies[51](index=51&type=chunk) - No foreign exchange hedging transactions or instruments were entered into during the reporting period[51](index=51&type=chunk) [Credit Risk](index=18&type=section&id=Credit%20Risk) The Group's primary credit risk arises from loans receivable, particularly money lending services, for which policies and procedures are established to mitigate risk, and assessments are conducted using a probability-weighted expected credit loss model - Primary credit risk originates from loans receivable, especially money lending services[52](index=52&type=chunk) - The Group has established policies and procedures to mitigate credit risk and assesses the recoverability of loans receivable using a probability-weighted expected credit loss model[52](index=52&type=chunk)[53](index=53&type=chunk) [Legal and Commitments](index=19&type=section&id=Legal%20and%20Commitments) There were no pledged assets or significant contingent liabilities at the end of the reporting period, while the Group faces litigation related to Beijing Hengjia and has filed for its judicial dissolution, with capital commitments significantly reduced [Pledged Assets](index=19&type=section&id=Pledged%20Assets) As of June 30, 2025, and December 31, 2024, the Group had no pledged assets - As of June 30, 2025, and December 31, 2024, there were no pledged assets[54](index=54&type=chunk) [Contingent Liabilities](index=19&type=section&id=Contingent%20Liabilities) As of June 30, 2025, and December 31, 2024, the Group had no significant contingent liabilities - As of June 30, 2025, and December 31, 2024, the Group had no significant contingent liabilities[55](index=55&type=chunk) [Litigation](index=19&type=section&id=Litigation) The Group has received a civil writ from Beijing Hengjia regarding unpaid registered capital of US$22.61 million, with the Board believing there are strong legal grounds to address the claim and having filed a lawsuit in a Chinese court for Beijing Hengjia's judicial dissolution - The Group has received a civil writ from Beijing Hengjia regarding unpaid registered capital of **US$22.61 million**[56](index=56&type=chunk) - The Board believes there are strong legal grounds to address the claim and may realize the investment to eliminate litigation uncertainty[56](index=56&type=chunk) - The Group has filed a lawsuit in a Chinese court seeking the judicial dissolution of Beijing Hengjia[56](index=56&type=chunk) [Capital Commitments](index=19&type=section&id=Capital%20Commitments) As of June 30, 2025, the Group had no capital commitments, a significant reduction from HK$134 thousand as of December 31, 2024 - As of June 30, 2025, the Group had no capital commitments (December 31, 2024: **HK$134 thousand** for the acquisition of property, plant, and equipment)[57](index=57&type=chunk) [Prospects](index=19&type=section&id=Prospects) The Group's future performance is influenced by economic conditions in Hong Kong and China, with Hong Kong experiencing solid expansion but weak private consumption, and China facing domestic consumption and real estate market challenges. The Group plans to enhance performance and liquidity through product diversification, channel expansion, product optimization, conservative investment strategies, and potential property disposals, while actively seeking new growth opportunities - Hong Kong's economy expanded steadily in the first quarter of 2025, but private consumption expenditure saw a slight decline[58](index=58&type=chunk) - China's economy faces risks including weak domestic consumption, a sluggish real estate market, Sino-US geopolitical tensions, and global trade protectionism[59](index=59&type=chunk) - The Chinese government has introduced various support measures, such as subsidies for old-for-new home appliances and relaxed fiscal policies, to counter external threats, stimulate domestic demand, and support high-tech industries[59](index=59&type=chunk) - The distribution segment aims to boost sales through product diversification, expanding distribution channels, and broadening its customer base[60](index=60&type=chunk) - The manufacturing segment is stabilizing operations of new healthy instant noodle production lines, expanding product categories (e.g., low-GI certified instant noodles), increasing own-brand market exposure, and enriching nutritional supplement categories[60](index=60&type=chunk) - The investment segment will adhere to a conservative strategy, closely evaluating and optimizing its investment portfolio, and may dispose of Chinese properties to replenish liquidity and mitigate market risks[60](index=60&type=chunk) - For the second half of 2025, the Group anticipates optimizing business segments to enhance sales and profitability, seeking cost reductions, potentially exiting loss-making projects, disposing of properties, and reallocating resources to promising segments[60](index=60&type=chunk) - The Group will prudently explore new potential growth opportunities, undervalued assets, and business expansion opportunities to diversify revenue streams, generate profits, and enhance shareholder value[60](index=60&type=chunk) [Other Information](index=20&type=section&id=Other%20Information) [Employees and Remuneration](index=20&type=section&id=Employees%20and%20Remuneration) As of June 30, 2025, the Group employed approximately 42 staff in Hong Kong and China, a decrease from 56 as of December 31, 2024, with remuneration determined by basic salary, bonuses, and benefits-in-kind, referencing industry practice and individual performance Number of Employees | Metric | June 30, 2025 | December 31, 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Number of Employees | 42 | 56 | -25.0% | - Staff remuneration is determined by basic salary, bonuses, and other benefits-in-kind, referencing industry practice and individual performance[61](index=61&type=chunk) - The Group provides induction training for new staff and regular training for existing employees[61](index=61&type=chunk) [Events After Reporting Period](index=21&type=section&id=Events%20After%20Reporting%20Period) Except as otherwise disclosed in this announcement, the Group had no significant events after the end of the reporting period - No significant events after the end of the reporting period were disclosed[62](index=62&type=chunk) [Purchase, Redemption or Sale of Listed Securities](index=21&type=section&id=Purchase%2C%20Redemption%20or%20Sale%20of%20Listed%20Securities) Neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities during the period - Neither the Company nor its subsidiaries purchased, sold, or redeemed any of the Company's listed securities during the reporting period[63](index=63&type=chunk) [Corporate Governance](index=21&type=section&id=Corporate%20Governance) The Group generally complied with the Corporate Governance Code during the reporting period, with deviations noted in the unseparated roles of Chairman and Chief Executive Officer and the Remuneration Committee's terms of reference not covering senior management remuneration. All Directors confirmed compliance with the Model Code for Securities Transactions, and the Audit Committee reviewed and approved the interim financial statements [Corporate Governance Practices](index=21&type=section&id=Corporate%20Governance%20Practices) The Group complied with all code provisions of Appendix C1 to the Listing Rules, "Corporate Governance Code," except for deviations regarding the unseparated roles of Chairman and Chief Executive Officer and the Remuneration Committee's terms of reference not covering senior management remuneration - The Group complied with all code provisions of Appendix C1 to the Listing Rules, "Corporate Governance Code," with two deviations[64](index=64&type=chunk) - Deviation C.2.1: Mr. Wang Liping serves as both Chairman and Chief Executive Officer, and the company is seeking a suitable candidate; the Board believes the existing balance of power adequately safeguards shareholders' interests[64](index=64&type=chunk) - Deviation E.1.2: The Remuneration Committee's terms of reference do not include reviewing senior management remuneration, as the Board believes executive directors are better suited for this role[65](index=65&type=chunk) [Model Code for Securities Transactions](index=22&type=section&id=Model%20Code%20for%20Securities%20Transactions) The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix C3 to the Listing Rules, and all Directors confirmed compliance with the required standards throughout the review period - The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix C3 to the Listing Rules[66](index=66&type=chunk) - All Directors confirmed compliance with the required standards of the Model Code throughout the review period[66](index=66&type=chunk) [Review by Audit Committee](index=22&type=section&id=Review%20by%20Audit%20Committee) The Audit Committee, established in accordance with the Corporate Governance Code and comprising three independent non-executive directors, has reviewed and approved the unaudited condensed consolidated financial statements for the six months ended June 30, 2025 - The Audit Committee has been established in accordance with the Corporate Governance Code and comprises three independent non-executive directors[67](index=67&type=chunk) - The Audit Committee has reviewed and approved the unaudited condensed consolidated financial statements for the six months ended June 30, 2025[67](index=67&type=chunk) [Publication of Interim Results and Report](index=22&type=section&id=Publication%20of%20Interim%20Results%20and%20Report) This interim results announcement has been published on the Company's website and the Stock Exchange's website, and the 2025 interim report containing all required information will be dispatched to shareholders and published on the aforementioned websites in due course - The interim results announcement has been published on the Company's website (www.egichk.com) and the Stock Exchange's website (www.hkexnews.hk)[68](index=68&type=chunk) - The 2025 interim report, containing all required information, will be dispatched to shareholders and published on the aforementioned websites in due course[68](index=68&type=chunk)